Brokerages Anticipate POINT Biopharma Global Inc. (NASDAQ:PNT) Will Announce Earnings of -$0.23 Per Share

Analysts expect POINT Biopharma Global Inc. (NASDAQ:PNTGet Rating) to report earnings of ($0.23) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for POINT Biopharma Global’s earnings, with estimates ranging from ($0.26) to ($0.19). POINT Biopharma Global posted earnings per share of ($0.15) during the same quarter last year, which indicates a negative year over year growth rate of 53.3%. The company is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that POINT Biopharma Global will report full year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.16) to ($0.76). For the next financial year, analysts expect that the firm will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.57) to ($0.76). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover POINT Biopharma Global.

POINT Biopharma Global (NASDAQ:PNTGet Rating) last posted its earnings results on Friday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03.

A number of research firms have issued reports on PNT. Jefferies Financial Group upgraded POINT Biopharma Global from a “hold” rating to a “buy” rating and lifted their target price for the company from $7.00 to $20.00 in a research report on Thursday, May 26th. Zacks Investment Research cut POINT Biopharma Global from a “hold” rating to a “sell” rating in a report on Tuesday, May 31st. Finally, Piper Sandler reduced their price target on POINT Biopharma Global from $17.00 to $14.00 and set a “na” rating on the stock in a report on Friday, May 13th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $29.00.

In other news, insider Neil E. Fleshner sold 564,204 shares of the company’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $7.51, for a total transaction of $4,237,172.04. Following the transaction, the insider now directly owns 3,023,045 shares of the company’s stock, valued at $22,703,067.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Large investors have recently made changes to their positions in the business. Franklin Resources Inc. bought a new position in POINT Biopharma Global in the 3rd quarter valued at $7,690,000. Suvretta Capital Management LLC grew its stake in POINT Biopharma Global by 20.1% in the 4th quarter. Suvretta Capital Management LLC now owns 2,672,863 shares of the company’s stock worth $14,968,000 after buying an additional 447,863 shares in the last quarter. Baskin Financial Services Inc. purchased a new position in POINT Biopharma Global in the 4th quarter worth approximately $1,004,000. Firethorn Wealth Partners LLC bought a new stake in shares of POINT Biopharma Global in the 4th quarter worth approximately $178,000. Finally, Claro Advisors LLC lifted its holdings in shares of POINT Biopharma Global by 52.3% in the 4th quarter. Claro Advisors LLC now owns 23,300 shares of the company’s stock worth $130,000 after acquiring an additional 8,000 shares during the last quarter. Hedge funds and other institutional investors own 41.76% of the company’s stock.

Shares of NASDAQ PNT traded down $0.34 during mid-day trading on Friday, reaching $6.25. The company had a trading volume of 545 shares, compared to its average volume of 476,998. POINT Biopharma Global has a one year low of $4.25 and a one year high of $11.72. The business’s 50-day simple moving average is $7.85 and its 200 day simple moving average is $6.90. The firm has a market cap of $563.25 million, a price-to-earnings ratio of -9.19 and a beta of -0.38.

POINT Biopharma Global Company Profile (Get Rating)

POINT Biopharma Global Inc, a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.

Featured Articles

Get a free copy of the Zacks research report on POINT Biopharma Global (PNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for POINT Biopharma Global (NASDAQ:PNT)

Want More Great Investing Ideas?

Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.